广东利元亨智能装备股份有限公司2024 年年度报告 公司代码：688499 公司简称：利元亨 广东利元亨智能装备股份有限公司 2024 年年度报告 1/320 广东利元亨智能装备股份有限公司2024 年年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 受动力锂电下游市场产能过剩影响，公司部分客户缩减或取消设备投资计划，同时行业竞争 加剧进一步压缩公司锂电设备订单的毛利率空间。尽管公司通过控本降费减少期间费用总额，但 受营收下滑影响，期间费用率仍处于较高水平，叠加银行借款及票据贴现规模扩大带来的财务费 用增长，进一步加重经营负担。此外，行业下行周期内部分项目验收周期拉长，导致公司在客户 现场的人力成本投入增加，下游客户面临阶段性经营困难导致现金流相对紧张，回款周期延长， 促使公司计提大额资产减值损失和信用减值损失，多重因素叠加导致公司经营业绩持续承压。未 来，若公司不能及时有效地应对上述不利因素的影响，公司经营业绩将 ...

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares [8]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development [6]. - In 2024, the company's operating revenue was CNY 274,850,777.34, a decrease of 42.77% compared to CNY 480,220,256.00 in 2023 [24]. - The net profit attributable to shareholders was a loss of CNY 19,981,182.92 in 2024, down 120.02% from a profit of CNY 99,828,173.71 in 2023 [24]. - The net cash flow from operating activities decreased by 49.00% to CNY 56,563,516.68 in 2024, compared to CNY 110,908,655.20 in 2023 [27]. - The company's total assets at the end of 2024 were CNY 1,053,411,101.81, down 8.39% from CNY 1,149,858,761.63 at the end of 2023 [24]. - The company reported a decrease in net assets attributable to shareholders by 9.37% to CNY 810,050,019.65 at the end of 2024 [24]. - The company faced increased competition and reduced customer investment willingness, impacting revenue negatively [26]. - The company’s revenue decreased due to fluctuations in downstream market demand and increased competition, leading to a decline in operating income [141]. Research and Development - Research and development expenses accounted for 14.70% of operating revenue in 2024, an increase of 7.79 percentage points from 6.91% in 2023 [25]. - The total R&D investment for the year reached ¥40,411,899.21, an increase of 21.81% compared to the previous year [111]. - The company submitted 146 new patent applications during the reporting period, including 21 invention patent applications [39]. - The company has received multiple accolades for its products, including recognition as the first domestic product in various categories from 2017 to 2024, highlighting its innovation and industry leadership [70]. - The company has established a comprehensive R&D system across eight major modules, enhancing its innovation and talent development efforts [124]. - The company has developed numerous core technologies in automated production, including high-speed multi-channel feeding technology and medical soft catheter shaping technology, which are leading in the domestic market [123]. - The company is actively engaged in the research and development of GLP-1 drugs to capitalize on the growing market [103]. Operational Risks and Compliance - The company faces potential operational risks, which are detailed in the report, emphasizing the need for investor caution [6]. - The audit report from Tianjian Accounting Firm confirmed a standard unqualified opinion, ensuring the accuracy of the financial statements [7]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity [10]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations [10]. - The company has established a comprehensive internal control system and governance mechanism to improve risk management and ensure compliance with legal regulations [40]. Market Trends and Industry Insights - The domestic medical consumables industry is experiencing continuous growth, driven by factors such as an aging population and increasing healthcare expenditures, with a projected steady growth trend [65]. - The intelligent manufacturing equipment industry in China is benefiting from strong government support and the integration of new information technologies, leading to rapid market growth and expansion opportunities [64]. - The demand for intelligent production equipment in the medical consumables sector is increasing due to stricter government regulations and rising labor costs, creating a favorable market environment for intelligent equipment manufacturers [66]. - The medical device market is experiencing a slowdown in growth, with investment amounts declining year-on-year [142]. Strategic Initiatives and Future Plans - The company has outlined its future plans and development strategies, which are subject to investment risks and do not constitute a commitment to investors [9]. - The company plans to invest in the "Annual Production of 35 Units of Medical Equipment Intelligent Equipment Expansion Project" to enhance production efficiency and supply capacity, utilizing part of the raised funds for this initiative [190]. - The company aims to become a global leader in medical consumables automation, focusing on enhancing technology levels and developing intelligent equipment to improve assembly efficiency and product quality for downstream manufacturers [188]. - The company intends to expand its market presence in Europe, the Americas, and developing countries, aiming to increase product market penetration and share [194]. Investor Relations and Governance - The company actively engages in investor relations to enhance communication and improve its image in the capital market [40]. - The company will strengthen investor relations management to protect minority shareholders' rights and ensure compliance with relevant laws and regulations [196]. - The company plans to optimize organizational management to enhance operational efficiency and competitiveness through improved governance structures and decision-making mechanisms [198].

Financial Performance - The company's revenue for Q1 2025 was CNY 474,310,296.66, representing a 6.97% increase compared to CNY 443,405,252.67 in the same period last year[3]. - Net profit attributable to shareholders decreased by 61.60% to CNY 29,448,437.25 from CNY 76,687,049.55 year-over-year[3]. - Basic and diluted earnings per share decreased by 66.67% to CNY 0.02 from CNY 0.06 in the previous year[3]. - Total operating revenue for Q1 2025 reached ¥474,310,296.66, an increase from ¥443,405,252.67 in Q1 2024, representing a growth of approximately 6.4%[16]. - Net profit for Q1 2025 was ¥29,448,437.25, a decrease from ¥76,687,049.55 in Q1 2024, reflecting a decline of approximately 61.5%[18]. - Earnings per share for Q1 2025 were ¥0.02, down from ¥0.06 in Q1 2024, showing a reduction of 66.7%[18]. Cash Flow - The net cash flow from operating activities fell by 46.72% to CNY 74,234,875.87, primarily due to increased cash payments for goods and services[3]. - Cash inflow from operating activities totaled $587,060,291.56, an increase from $567,931,452.87 in the previous period, reflecting a growth of approximately 2.0%[20]. - Cash outflow from operating activities was $512,825,415.69, compared to $428,605,573.13 previously, indicating an increase of about 19.7%[20]. - Net cash flow from operating activities decreased to $74,234,875.87 from $139,325,879.74, representing a decline of approximately 46.6%[20]. - Cash inflow from investment activities was $2,517,759,615.21, significantly up from $430,357,193.97, marking an increase of around 485.5%[20]. - Cash outflow from investment activities rose to $2,522,894,583.03 from $665,098,796.56, reflecting an increase of about 278.5%[20]. - The net cash flow from investment activities was -$5,134,967.82, an improvement from -$234,741,602.59 in the previous period[21]. - Cash inflow from financing activities was $41,275,200.00, compared to no inflow in the previous period[21]. - Cash outflow from financing activities decreased to $67,743,716.58 from $244,758,183.85, a reduction of approximately 72.3%[21]. - The net cash flow from financing activities was -$67,743,716.58, improving from -$203,482,983.85 previously[21]. - The ending cash and cash equivalents balance was $988,482,353.22, up from $1,826,573,159.78 at the beginning of the period[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,921,485,746.87, a slight decrease of 0.99% from CNY 6,991,013,658.68 at the end of the previous year[4]. - Current assets decreased to CNY 2,190,362,208.87 from CNY 2,355,381,006.67, indicating a decline of approximately 7.0%[12]. - Cash and cash equivalents increased to CNY 988,482,353.22 from CNY 984,490,583.43, showing a growth of about 0.2%[12]. - The company's inventory rose to CNY 507,551,173.41 from CNY 468,474,132.37, reflecting an increase of approximately 8.4%[12]. - Short-term borrowings decreased significantly to CNY 94,614,827.96 from CNY 135,963,108.63, a reduction of about 30.4%[13]. - Total current liabilities decreased to CNY 643,825,685.08 from CNY 712,792,356.26, representing a decline of approximately 9.7%[13]. - Total liabilities decreased to ¥873,295,337.32 in Q1 2025 from ¥987,721,636.48 in Q1 2024, a reduction of about 11.6%[14]. - Total equity attributable to shareholders increased to ¥6,048,190,409.55 in Q1 2025 from ¥6,003,292,022.20 in Q1 2024, reflecting a growth of approximately 0.75%[14]. Research and Development - Research and development expenses totaled CNY 43,374,981.57, a 40.77% increase from CNY 30,812,790.94, accounting for 9.14% of revenue[3][4]. - Research and development expenses for Q1 2025 were ¥43,374,981.57, compared to ¥30,812,790.94 in Q1 2024, marking an increase of about 40.6%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,752[7]. - The company has a major shareholder, Hefei Qizhong Technology Holding Co., Ltd., holding 33.40% of shares[8]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 33%[8]. Other Financial Metrics - The weighted average return on equity dropped by 0.82 percentage points to 0.49% from 1.31%[3]. - The company reported non-recurring gains and losses totaling CNY 465,771.35, with a significant portion attributed to asset disposal losses[5][6]. - The decline in net profit was mainly due to increased costs related to equipment depreciation, stock incentives, and labor expenses[6]. - The company reported a significant decrease in employee compensation liabilities, dropping to CNY 29,001,600.41 from CNY 70,641,541.97, a decline of approximately 58.9%[13].

昱能科技股份有限公司2025 年第一季度报告 证券代码：688348 证券简称：昱能科技 昱能科技股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 | | | --- | --- | --- | --- | | | | 上年同期 年同期增减变 | | | | | 动幅度(%) | | | 营业收入 | 190,809,757.15 | 427,748,061.08 | -55.39 | | 归属 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 104,099,813.81, representing a 16.77% increase compared to CNY 89,152,510.16 in the same period last year[4] - Net profit attributable to shareholders reached CNY 17,870,494.14, a significant increase of 328.63% from CNY 4,169,185.75 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0380, reflecting a 326.97% increase from CNY 0.0089 in the same quarter last year[4] - Operating profit for Q1 2025 was CNY 17,932,298.02, significantly up from CNY 6,181,921.57 in Q1 2024, marking a 189.5% increase[18] - Total comprehensive income for Q1 2025 was CNY 17,869,070.17, compared to CNY 4,169,185.75 in Q1 2024, an increase of 328.5%[19] Cash Flow - The net cash flow from operating activities surged to CNY 34,790,900.13, marking a 455.68% increase compared to CNY 6,260,970.00 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was CNY 123,477,571.15, compared to CNY 96,586,955.28 in Q1 2024, reflecting a 28.0% increase[19] - The net cash flow from investment activities was $34,944,133.15, a decrease from $129,739,268.51, indicating a decline in investment returns[20] - Cash inflow from financing activities was $379,881.15, with cash outflow totaling $899,061.79, leading to a net cash flow of -$519,180.64, down from -$2,414,583.20[20] - The net increase in cash and cash equivalents was $69,647,538.18, compared to $133,483,193.37 in the previous period, showing a decrease of approximately 47.9%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,878,666.43, a 1.28% increase from CNY 1,893,682,970.18 at the end of the previous year[5] - The total current liabilities rose to RMB 117,874,688.02, compared to RMB 108,269,002.11 in the previous period, indicating an increase of about 8%[16] - The total liabilities of the company were reported at RMB 155,577,442.98, slightly up from RMB 151,946,998.96, marking a growth of around 2%[16] - The company's equity increased to RMB 1,762,301,223.45, compared to RMB 1,741,735,971.22, reflecting a growth of approximately 1.2%[16] Research and Development - Research and development expenses totaled CNY 20,692,617.34, a decrease of 10.80% from CNY 23,197,241.84, with R&D expenses accounting for 19.88% of operating revenue[5] - Research and development expenses decreased to CNY 13,417,634.91 in Q1 2025 from CNY 19,762,555.02 in Q1 2024, a reduction of 32.1%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,764, with the top ten shareholders holding a combined 73.23% of the shares[11] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders during the reporting period[13] Other Financial Metrics - The company reported non-recurring gains of CNY 5,310,185.97, primarily due to government subsidies and asset disposals[7] - The weighted average return on equity increased to 1.02%, up by 0.77 percentage points from 0.25%[4] - The company reported a foreign exchange loss of CNY 1,423.97 in Q1 2025[18] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[21]

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares[4]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[3]. - The company's operating revenue for 2024 was CNY 417.80 million, a 1.57% increase from CNY 411.36 million in 2023[22]. - The net profit attributable to shareholders for 2024 was a loss of CNY 141.20 million, compared to a loss of CNY 76.07 million in 2023, representing an 85.63% decrease year-over-year[22][24]. - The net cash flow from operating activities for 2024 was a negative CNY 37.50 million, an improvement from a negative CNY 166.22 million in 2023[22]. - The company's total assets increased by 7.04% to CNY 1.87 billion at the end of 2024, up from CNY 1.75 billion at the end of 2023[23]. - The basic earnings per share for 2024 was CNY -0.34, a decrease of 88.89% compared to CNY -0.18 in 2023[22]. - The weighted average return on net assets for 2024 was -13.42%, a decrease of 6.86 percentage points from -6.56% in 2023[22]. - The company reported a non-recurring loss of 55.70 million yuan from the disposal of non-current assets in 2023[28]. - The company received government subsidies amounting to 25.79 million yuan in the reporting period, down from 63.39 million yuan in the previous year[29]. - The company's total revenue for the reporting period was CNY 41,780.47 million, an increase of 1.57% compared to the previous year[178]. - The net profit attributable to shareholders was CNY -14,120.43 million, a decrease of 85.63% year-on-year[178]. Research and Development - Research and development expenses accounted for 25.73% of operating revenue in 2024, an increase of 5.27 percentage points from 20.46% in 2023[22][24]. - The total R&D investment for the year was approximately ¥107.5 million, representing a 27.70% increase compared to the previous year[141]. - The proportion of total R&D investment to operating income increased by 5.27 percentage points to 25.73%[141]. - The company has 27 ongoing research projects, including 7 Class 1 new drugs and 3 Class 2 new drugs, with two Class 1 innovative HIV drugs, AINOVIR and AINOMITE, approved and commercialized[61]. - The company is focusing on the development of long-acting HIV drugs, with ongoing preclinical research on lead compounds[144]. - The company has achieved significant advancements in the synthesis of key raw materials for drugs ACC007, ACC010, ACC015, and ACC017, focusing on high purity and low-cost production methods[136]. - The company has established a small molecule drug research and development platform and a human-derived protein research and development platform, focusing on project management and technical development[92]. - The company has completed the small-scale development of a single-tablet regimen for HIV patients, enhancing convenience for treatment[146]. - The company has developed multiple formulation technologies, including ACC008, which addresses solubility and stability issues of active ingredients[137]. - The company has completed enrollment for all subjects in a Phase Ib/IIa clinical study for initial HIV-infected patients, with preliminary results indicating good safety and clear efficacy of the ACC017 tablet[158]. Product Development and Innovation - The company is in the process of developing new products and technologies, although specific details were not provided in the summary[5]. - The company is actively advancing its research pipeline, with the ACC017 integrase inhibitor I phase clinical trial progressing smoothly and a patent granted[36]. - The company is developing a combination formulation centered on ACC017, which has completed small-scale and pilot studies and is advancing towards IND registration[37]. - The company is focusing on enhancing its innovation capabilities in the HIV treatment sector, aiming to meet the urgent domestic demand for HIV treatment[33]. - The company is committed to building a global industry layout based on its core areas of HIV antiviral and human protein[34]. - The company is actively pursuing clinical trials and regulatory approvals for its innovative drug candidates, positioning itself for future market expansion[136]. - The company has developed a proprietary technology for the preparation of epidermal growth factor from urine, enhancing its product portfolio in regenerative medicine[135]. - The company has established preliminary quality standards for long-acting low molecular weight heparin sodium freeze-dried powder injections, with a total investment of 15,000,000.00 RMB[150]. - The company has completed the production batch verification for ACC017 and is progressing with stability studies[144]. - The company has achieved a significant milestone with the completion of raw material drug process development for high molecular weight urokinase, with clinical research ongoing[146]. Market and Sales Performance - The total sales revenue from HIV new drugs reached CNY 149.9 million, representing a year-on-year growth of 103.73%, indicating positive progress in commercialization efforts[48]. - The revenue from the HIV new drug Aino Mite tablet reached CNY 133.54 million, a significant increase of 173.41% year-on-year[186]. - The sales volume of Urokinase crude product decreased by 24.07%, while inventory increased by 81.25%[189]. - The production volume of Aino Mite tablet increased by 185.39%, with sales volume rising by 127.07%[190]. - The company has strengthened its position in the domestic HIV innovative drug market, becoming one of the leading enterprises in this sector[123]. - The company is actively expanding its international business, with ongoing audits of overseas suppliers and the gradual development of business collaborations[51]. - The company has established a marketing strategy focused on "medical guidance, market pull, and sales implementation," enhancing brand recognition and product accessibility[165]. - The company is actively expanding its overseas market presence, particularly in Africa and Southeast Asia, to create new business growth points[166]. - The company plans to continue the commercialization of its HIV new drug and expand into overseas markets in 2025[170]. - The company is focused on promoting new products and expanding market reach following recent acquisitions and product approvals[186]. Compliance and Governance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy of the financial statements[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, indicating financial integrity[6]. - The company has not violated decision-making procedures for external guarantees, ensuring compliance with regulations[7]. - The company has not disclosed any special arrangements in corporate governance, suggesting standard practices are in place[8]. - The company emphasizes the affordability of its innovative drugs, contributing to reduced patient burden and significant savings for national healthcare funds[74]. Risks and Challenges - The company has outlined various risk factors in its operations, which investors should consider when making investment decisions[3]. - The company faces risks related to the commercialization of its innovative drugs and potential delays in project implementation[174]. - The company has not provided specific future performance guidance or projections, reflecting a cautious outlook[5]. - The company has reported a 66.59% decrease in labor costs for urine activator crude products compared to the previous year[193]. - The company did not report any significant changes or adjustments in its business, products, or services during the reporting period[196].

Financial Performance - The company reported a total operating revenue of 397.68 million yuan for the fiscal year 2024, with a net loss attributable to shareholders of 695.69 million yuan[5]. - The net profit excluding non-recurring gains and losses was reported at a loss of 722.32 million yuan[5]. - The company has not declared any cash dividends, stock dividends, or capital reserve transfers to shareholders for the fiscal year 2024 due to existing losses and significant future R&D funding needs[8]. - The company's operating revenue for 2024 was approximately RMB 397.68 million, representing a decrease of 36.69% compared to RMB 628.12 million in 2023[35]. - The net profit attributable to shareholders for 2024 was approximately RMB -695.69 million, compared to RMB -643.46 million in 2023, indicating a worsening financial position[35]. - The basic earnings per share for 2024 was -0.67 yuan, a decline from -0.62 yuan in 2023[36]. - The weighted average return on equity for 2024 was -51.37%, a decrease of 16.33 percentage points from -35.04% in 2023[36]. - The total assets at the end of 2024 were approximately RMB 1.98 billion, down 27.88% from RMB 2.75 billion at the end of 2023[35]. - The net assets attributable to shareholders decreased to approximately RMB 1.12 billion, a decline of 31.11% from RMB 1.62 billion in 2023[35]. - The cash flow from operating activities for 2024 was approximately RMB -307.05 million, worsening from RMB -239.75 million in 2023[35]. Shareholder Structure - The controlling shareholder, Changzhou Cloud, holds 205,107,480 Class A shares, which represent 19.78% of total shares but account for 59.67% of voting rights[13]. - The company has implemented a special voting rights system, where each Class A share has 6 votes compared to 1 vote for each Class B share[10]. - The total number of shares held by other shareholders is 831,831,307, representing 80.22% of total shares and 40.33% of voting rights[13]. Risk Management - The company has outlined various risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[16]. - The company’s future plans and projections are subject to risks and do not constitute substantive commitments to investors[15]. Revenue Growth and Projections - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in the last quarter[22]. - User data showed an increase in active users, reaching 5 million, which represents a 15% growth compared to the previous quarter[23]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20%[22]. - New product launches are expected to contribute an additional $50 million in revenue over the next fiscal year[23]. - The company reported a significant increase in revenue, reaching $1.5 billion, representing a 25% year-over-year growth[24]. - User data showed a 30% increase in active users, totaling 10 million users by the end of the quarter[24]. - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next quarter, aiming for $1.8 billion[24]. Research and Development - The company is investing in AI technology, with a budget allocation of $10 million for research and development in the upcoming year[22]. - Research and development expenses increased by 10%, totaling $300 million, focusing on innovative technologies[25]. - Research and development expenses accounted for 119.26% of operating revenue in 2024, an increase of 27.29 percentage points from 91.97% in 2023[36]. - The total R&D investment amounted to ¥474,276,336.64, a decrease of 17.90% compared to the previous year, with R&D expenses accounting for 119.26% of operating revenue, an increase of 27.29 percentage points[181]. - The company is involved in 18 major scientific research projects, with 8 projects in the "under research" stage and 7 projects in the "application for conclusion" stage as of the end of the reporting period[179]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of the fiscal year, targeting a 10% market share in each[23]. - The company is considering strategic acquisitions to enhance its technology portfolio, with a potential budget of $100 million for acquisitions[22]. - The company is focusing on enhancing its algorithmic platforms and expanding its user base through innovative product offerings[34]. - The company is exploring partnerships with independent software vendors to enhance its product offerings and market reach[25]. Technology and Innovation - The company is focusing on AI innovation and digital transformation, supported by national policies aimed at enhancing the AI industry[50]. - The company has successfully implemented demonstration projects in anti-money laundering and financial internal control, showcasing its capabilities in the financial and governmental sectors[51]. - The company emphasizes ethical standards in AI development, ensuring the safety and reliability of its technologies[52]. - The company is actively participating in the formulation of industry standards for sustainable AI development, promoting a harmonious coexistence of humans and machines[52]. - The company has developed a human-machine collaboration operating system and AIoT devices, focusing on AI solutions for specific industry problems[82]. - The company’s AI model received recognition as one of the top three globally in the Open Compass multi-modal evaluation, further establishing its industry leadership[76]. - The company has established a cross-regional computing network in the Yangtze River Delta, enhancing resource allocation flexibility and reducing computing costs for enterprises[159]. Awards and Recognition - The company has been recognized as one of the "Top 20 AI Leading Enterprises of 2024" and "Top 50 AI Companies in China" for its advancements in AI technology[156]. - The company received multiple awards, including the "2024 Shanghai Science and Technology Award" and recognition as one of the "Top 30 High-tech Enterprises in Nansha District" as of the end of the reporting period[176]. Patents and Intellectual Property - The company holds a total of 393 patents, including 242 invention patents, 42 utility model patents, and 109 design patents, with 72 new patents granted during the reporting period[177]. - The company has filed multiple patents related to its core technologies, indicating a robust pipeline for future product development and innovation[160]. - The company holds multiple patents related to its advanced technologies, including over 10 patents for the multimodal models and their applications[162]. Future Outlook - The company plans to continue investing in new technologies and market expansion strategies to improve future performance[34]. - The company is committed to continuous service improvement and algorithm upgrades, ensuring that its solutions remain effective and relevant in a rapidly changing market[126]. - The company aims to enhance model training and service efficiency through an automated production system, which is expected to significantly reduce project delivery costs[197].

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,176,271.66, a decrease of 45.87% compared to ¥74,220,852.42 in the same period last year[3] - The net profit attributable to shareholders was -¥10,797,370.24, representing a decline of 202.7% from a profit of ¥10,513,161.20 in the previous year[3] - The basic earnings per share were -¥0.07, a decrease of 216.67% from ¥0.06 in the same period last year[3] - The diluted earnings per share also stood at -¥0.07, showing a decline of 216.67% compared to the previous year's ¥0.06[3] - The weighted average return on equity was -1.34%, a decrease of 2.51 percentage points from the previous year's 1.17%[3] - The net loss for Q1 2025 was CNY 13,352,887.54, compared to a net profit of CNY 9,614,159.23 in Q1 2024, indicating a significant decline in profitability[19] - The total equity attributable to shareholders decreased to CNY 784,825,447.22 in Q1 2025 from CNY 810,050,019.65 in Q1 2024, a decline of 3.1%[17] Cash Flow - The net cash flow from operating activities increased by 187.24% to ¥29,713,887.51, up from ¥10,344,617.70 in the same period last year[3] - Cash flow from operating activities for Q1 2025 was $29,713,887.51, a significant increase from $10,344,617.70 in Q1 2024, representing a growth of 187.5%[22] - Total cash inflow from investment activities in Q1 2025 was $146,353,661.00, compared to $5,330,784.87 in Q1 2024, indicating a substantial increase[22] - Net cash outflow from investment activities was -$35,241,358.69 in Q1 2025, worsening from -$23,828,213.47 in Q1 2024[23] - Cash flow from financing activities generated a net inflow of $4,822,770.54 in Q1 2025, compared to an inflow of $890,109.18 in Q1 2024[23] - The company reported a net cash increase of -$627,811.49 in Q1 2025, compared to -$12,378,088.04 in Q1 2024, showing an improvement in cash flow dynamics[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,088,739,539.60, reflecting a 3.35% increase from ¥1,053,411,101.81 at the end of the previous year[4] - Total liabilities rose to CNY 271,484,133.79 in Q1 2025, up from CNY 207,957,231.30 in Q1 2024, marking an increase of 30.6%[17] - The company's total assets increased to CNY 1,088,739,539.60 in Q1 2025 from CNY 1,053,411,101.81 in Q1 2024, representing a growth of 3.4%[17] Research and Development - Research and development expenses totaled ¥9,155,975.84, accounting for 22.79% of operating revenue, an increase of 9.48 percentage points from 13.31%[4] - Research and development expenses for Q1 2025 were CNY 9,155,975.84, slightly down from CNY 9,880,803.80 in Q1 2024, showing a decrease of 7.3%[18] Share Repurchase - As of March 31, 2025, the company has repurchased a total of 2,592,575 shares, accounting for 1.56% of the total share capital of 166,219,690 shares[12] - The total amount spent on share repurchase is RMB 29,156,636.67, with a maximum transaction price of RMB 13.45 per share and a minimum of RMB 9.30 per share[12] - The company plans to use repurchased shares for employee stock ownership plans or equity incentives, with a repurchase budget between RMB 15 million and RMB 30 million[11] Market Conditions - The decline in revenue and net profit was primarily attributed to fluctuations in downstream market demand and reduced customer investment willingness[6] Shareholder Information - The top ten shareholders hold a combined 47.15% of the shares, with Lin Junhua being the largest shareholder at 47.15%[9] - The company has not identified any related party relationships among the top ten shareholders, except for Lin Junhua's connection with Taizhou Saina Investment Consulting Partnership[10] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[10]

Financial Performance - The company's operating revenue for Q1 2025 was ¥168,492,571.31, a decrease of 6.36% compared to ¥179,943,616.32 in the same period last year[4] - Net profit attributable to shareholders decreased by 71.00% to ¥2,028,242.28 from ¥6,993,000.48 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥1,956,263.87, down 59.27% from ¥4,803,111.41 in the previous year[4] - Basic and diluted earnings per share fell by 71.07% to ¥0.0105 from ¥0.0363 in the same quarter last year[5] - Net profit for Q1 2025 was ¥946,000.25, a significant decline of 73.9% from ¥3.64 million in Q1 2024[20] - The company reported a total comprehensive income of ¥1.32 million for Q1 2025, down from ¥4.31 million in Q1 2024[20] Research and Development - Research and development expenses totaled ¥42,739,035.56, representing 25.37% of operating revenue, a slight decrease from 25.66% year-on-year[5] - The company has ongoing research and development efforts, particularly in data resources, with development expenditures of ¥20,416,181.77[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,874,378,372.87, down 3.81% from ¥1,948,633,609.09 at the end of the previous year[5] - The company's current assets totaled ¥1,540,914,105.75, down from ¥1,624,856,724.95 at the end of 2024, indicating a decline of approximately 5.2%[14] - The company's cash and cash equivalents decreased to ¥175,455,586.62 from ¥318,657,749.04, representing a decline of about 45%[14] - The accounts receivable stood at ¥557,432,939.08, slightly down from ¥594,496,868.84, reflecting a decrease of approximately 6.2%[14] - The company's total liabilities were ¥807,637,335.76, down from ¥922,815,801.50, indicating a reduction of about 12.5%[16] - The company's equity attributable to shareholders increased to ¥922,889,637.90 from ¥906,053,836.69, showing a growth of approximately 1.9%[16] Cash Flow - The net cash flow from operating activities improved to -¥45,030,725.73, an improvement from -¥71,724,455.08 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥45.03 million in Q1 2025, an improvement from a net outflow of ¥71.72 million in Q1 2024[23] - Cash flow from investing activities resulted in a net outflow of ¥70.36 million in Q1 2025, compared to a net outflow of ¥9.39 million in Q1 2024[24] - Cash flow from financing activities recorded a net outflow of ¥27.87 million in Q1 2025, contrasting with a net inflow of ¥64.07 million in Q1 2024[24] Market Expansion - The company signed a framework agreement for the "Democratic Republic of the Congo National Backbone Fiber Optic Broadband Network Project" with a total budget of $1.5 billion (excluding tax)[11] - The company is actively pursuing market expansion opportunities, as evidenced by the significant contract signed for the broadband network project[11]

Financial Performance - Revenue for Q1 2025 was CNY 90,724.64 million, a decrease of 69.57% compared to the same period last year[4] - Net profit attributable to shareholders was CNY -55,801.54 million, representing a decline of 268.78% year-on-year[4] - Basic earnings per share were CNY -0.26, down 273.33% from CNY 0.15 in the previous year[4] - Total operating revenue for Q1 2025 was ¥907,246,402.70, a significant decrease of 69.6% compared to ¥2,981,638,964.33 in Q1 2024[25] - The net loss for Q1 2025 was ¥558,015,371.85, compared to a net profit of ¥330,613,498.00 in Q1 2024, indicating a shift in performance[26] - Basic earnings per share for Q1 2025 were -¥0.26, compared to ¥0.15 in Q1 2024, showing a decline in shareholder value[26] Research and Development - Research and development expenses totaled CNY 4,118.36 million, a reduction of 69.89% compared to CNY 13,677.07 million last year[5] - Research and development expenses for Q1 2025 were ¥3,689,559.58, down from ¥11,032,870.24 in Q1 2024, a decrease of 66.6%[25] Cash Flow - Cash flow from operating activities was CNY -81,072.17 million, reflecting a significant decline due to reduced revenue[4] - The net cash flow from operating activities for Q1 2025 was -RMB 81.07 million, an improvement from -RMB 166.80 million in the same period last year[18] - The adjusted net cash flow from operating activities was -RMB 37.64 million, showing a decrease in cash loss compared to -RMB 99.78 million year-over-year[18] - In Q1 2025, the cash inflow from operating activities was CNY 408,070,236.54, a decrease of 59.5% compared to CNY 1,008,295,853.99 in Q1 2024[27] - The net cash outflow from operating activities was CNY -810,721,733.62, improving from CNY -1,668,028,219.69 in the same period last year[27] - The total cash outflow for operating activities was CNY 1,218,791,970.16, a decrease of 54.5% from CNY 2,676,324,073.68 in Q1 2024[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,316,607.33 million, down 2.34% from the end of the previous year[5] - The company's total assets amounted to RMB 43.17 billion, a decrease from RMB 44.20 billion at the end of 2024[20] - Total liabilities decreased from ¥4,042,508,028.88 in the previous period to ¥3,564,191,621.95, a reduction of approximately 11.8%[23] - The total equity attributable to shareholders decreased from ¥40,157,741,287.32 to ¥39,601,881,656.05, reflecting a decline of 1.4%[23] - The total liabilities and equity decreased from ¥44,200,249,316.20 to ¥43,166,073,278.00, a decline of approximately 2.3%[23] Production and Sales - In Q1 2025, the company produced 24,810 tons of polysilicon, a decrease of 60.2% year-over-year, and sold 28,008 tons, down 48.1% from the previous year[14] - The average selling price per kilogram was RMB 35.90, a decline of 34.6% compared to RMB 54.92 in Q1 2024, while the unit cost increased by 15.4% to RMB 53.08[14] - The company expects total production for 2025 to be between 110,000 and 140,000 tons, with Q2 production projected at 25,000 to 28,000 tons[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,011[9] - Daqo New Energy Corp. held 71.40% of the shares, with a total of 1,531,718,500 shares[9] Investment Activities - The company reported an investment income of ¥43,529,209.75 in Q1 2025, indicating a positive return compared to no investment income reported in Q1 2024[25] - The company reported a significant cash outflow of CNY 6,175,000,000.00 for investments in Q1 2025[28] - The cash inflow from investment activities totaled CNY 5,077,705,369.73, with a net cash outflow of CNY -2,050,160,736.24, compared to a net outflow of CNY -548,307,632.91 in Q1 2024[28] Inventory and Financial Optimization - Inventory as of March 31, 2025, was RMB 1.01 billion, down from RMB 1.20 billion at the end of 2024[21] - The company is focusing on inventory digestion and financial optimization to mitigate the impacts of the ongoing price decline in the polysilicon industry[13] Share Repurchase Plan - The company plans to repurchase shares with a total amount not less than RMB 50 million and not exceeding RMB 100 million, at a price not exceeding RMB 44 per share[12]